Evolus Reports Strong Revenue Growth, Shares Surge 16.08%

Evolus, Inc. reported significant revenue growth, with a preliminary Q4 revenue increase of 30%. Projected revenues for 2025 show continued positive momentum. The stock jumped 16.08% in pre-market trading as investors react positively to the news.

Date: 21-01-2025

AI Rating: 8

Revenue Growth: Evolus reported a substantial increase in revenue for both Q4 and the full year of 2024. Specifically, Q4 revenue reached $79 million, marking a 30% rise compared to the same quarter last year. For the full year, revenues totaled $266.3 million, indicating a 32% growth year-over-year.

Looking ahead, Evolus projects revenues between $345 million and $355 million for 2025, which translates to a robust growth expectation of 30% to 33% over preliminary 2024 figures. Additionally, the company anticipates that Evolyse and Estyme injectable HA gels will constitute 8% to 10% of total revenue for the full year of 2025.

This optimistic outlook and reported growth in market share, particularly in the U.S. neurotoxin market with Jeuveau, may lead to a positive investor sentiment and potential influence on stock prices.

Stocks: EOLS